TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: postoperative tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: NO levels in venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Combined major and minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day composite incidence of adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean inhibition of ex vivo platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of analgesia with NRS < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of T790M mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vigilant-avoidant patterns of emotional attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General startle responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for symptom management support
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in European Stroke Scale (ESS) motor score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine consumption at postoperative day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in remnant-like lipoprotein particle cholesterol (RLP-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in lumbar hypomobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rates with manipulation and stabilization
Endpoint domain: Adverse events/effects
Primary endpoint: Preterm birth (PTB) less than 37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: ST-segment elevation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abdominal fat area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage change of the thrombus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corrected Thrombolysis in Myocardial Infarction frame count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of lethal prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients requiring bolus doses of ephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vomiting 24 hours after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Rankin scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extension or recurrence of neurological deficits
Endpoint domain: Adverse events/effects
Primary endpoint: need for allogeneic blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: OCD outcome score at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSA score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPIC urinary incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPIC hormonal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge of prescription drug benefits and side effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correct identification of drug effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Choice of proton-pump inhibitor over histamine-2 blocker
Endpoint domain: Life impact
Endpoint subdomain: Decision making
Primary endpoint: Improvement in DLQI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Rating Scale score for Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of preterm birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weight (BWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of secondary osteomyelitis
Endpoint domain: Adverse events/effects
Primary endpoint: Requirements for supplemental IV fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: luteal phase serum testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of cycles with multiple dominant follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work-related well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in SSB kcals/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive treatment-related cost of COPD stage II+
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subjective effects involving concentration and arousal
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone area fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marrow area fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mineral area fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs of one-stage vs two-stage IBBR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of retained products of conception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obtaining competitive work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Social return on investment
Endpoint domain: Resource use
Primary endpoint: Overall accuracy of rectal contrast CT for diagnosis of acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease recurrence and/or progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IL-8 levels in responders vs nonresponders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke events
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial infarction events
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Achievement of treatment goal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of cardiovascular complications
Endpoint domain: Mortality/survival
Primary endpoint: Intercourse satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Orgasmic function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall satisfaction with sexual experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peritonitis episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Exit-site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Phagocytic capacity of PMphis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arterial Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Lipid Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Glucose Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of IL-6 in CSF and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caloric intake in absence of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of oral xylitol solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acceptance of study solution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abdominal pain relief rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first recurrence
Endpoint domain: Mortality/survival
Primary endpoint: proportions of patients having a second breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Health-related quality of life for children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: decrease of bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: improvement in corneal shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gross hematuria
Endpoint domain: Adverse events/effects
Primary endpoint: Objective pain score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Subjective fatigue ratings
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Indices of heart rate variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with guidelines for sexual history taking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Examination of both partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigation of both partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intraabdominal abscess
Endpoint domain: Adverse events/effects
Primary endpoint: HLA-DR expression on monocyte surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of systemic endotoxin and inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: freedom from headache pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MCA PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MCA PI/UA PI ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Disease progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of immobility-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma malondialdehyde concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean apparent population clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inter-occasion variability in clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-esteem score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: acute postoperative urinary retention
Endpoint domain: Adverse events/effects
Primary endpoint: peak urinary flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Ovarian response measured by oocytes recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ongoing pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC (Area Under the Curve) for esomeprazole and ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum Concentration) for esomeprazole and ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Debrunner kyphometer reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sample size attainment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of planned case conferences achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in severity of illness within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic exposure profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucodynamic potency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migraine-specific quality of life impairments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: suspicious optic nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ocular hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: retinal pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: LV hypertrophy reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Household smoking ban prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall absorption of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal vasoconstrictive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: arm circumference difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioimpedance difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCQ stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional connectivity between the right and left auditory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain/discomfort during TVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with follow-up scan
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percentage change in glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximal FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MV (Minute Ventilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HBc IgM antibody seroclearance achievement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain intensity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of clozapine formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interpersonal-room interaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative seroconversion rates of anti‐PF4/heparin Ab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CVD-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjunctive medication requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation between calculated and measured dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin homogeneity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin(V50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: darbepoetin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HL recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: good radiographic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity response at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative distribution of MED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reappearance of CMA symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma PAF‐AH activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ASI (Acne Severity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall disease assessment (patient and physician global assessment)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in skin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: % FVC predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥50% eGFR decline or dialysis events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in gingival thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of nucleotide substitutions per site per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to vaginal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant survival/success rate
Endpoint domain: Mortality/survival
Primary endpoint: Plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Calculus index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Effectiveness of moxifloxacin as monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiac Index (CI) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of agreement between original and regrading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular volume (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum insulin-like growth factor-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AF recurrence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of SCC in chronic, nonhealing DFU
Endpoint domain: Mortality/survival
Primary endpoint: Mean improvement in BCVA letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or 4 hepatotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' likelihood to show booklets to others
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patients' perceived usefulness of booklets
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' perceived understanding of their cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Deaths due to nonarrhythmic cardiac causes
Endpoint domain: Mortality/survival
Primary endpoint: Intake of monounsaturated fat (MUFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intake of vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes